Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates

Stock Information for Akoya BioSciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akoya BioSciences Inc.

AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal
Akoya Biosciences Reports First Quarter 2025 Financial Results
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA
Quanterix and Akoya Biosciences Announce Amended Merger Agreement
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AKYA, WTMA, PLYA, QTRX to Act Now
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PPBI, SSBK, AKYA on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pacific Premier Bancorp, Inc. (Nasdaq - PPBI), Southern States Bancshares, Inc. (Nasdaq - SSBK), Akoya Biosciences, Inc. (Nasdaq - AKYA)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.